Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses potential advancements in two hair loss drugs, KX-826 and GT20029, and the interest in whether transitioning from oral finasteride to these drugs would maintain hair growth. One reply expresses skepticism about the compounds' representation.

A 57-year-old man with male pattern hair loss and insulin resistance experienced hair regrowth and weight loss after using tirzepatide, without other hair treatments. Dysregulated glucose metabolism is linked to hair loss, with tirzepatide potentially improving hair density by normalizing insulin resistance.

The conversation discusses using a multimodal approach to treat androgenic alopecia, including substances like gamma-linolenic acid, DHA, sulforaphane, melatonin, cetirizine, astaxanthin, fisetin, apigenin, curcumin, limonene, genistein, and berberine. Users also mention using ketoconazole, minoxidil, and low-level laser therapy (LLLT) as part of their hair loss treatment regimens.

The user shared their experience with CB-03-01 (Breezula/Clascoterone) for hair loss, noting reduced shedding and improved hair appearance but experiencing significant sleep disturbances and low energy due to HPA axis suppression. They decided to stop using it due to these side effects and are waiting for GT20029 as an alternative.

The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.

The conversation discusses the results of a group buy for Ky19382 related to hair loss treatments. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

Kx-826 at 0.5% shows limited effectiveness for hair loss, while 1% is more promising but expensive. RU58841 is considered a more feasible option until 1% kx-826 becomes affordable.

The user is happy with hair regrowth after using finasteride, minoxidil, and microneedling for three months. Others comment on the progress and ask about the routine, lighting, and potential side effects.

The conversation discusses hair loss treatments, with the original poster considering joining a clinical trial for setipiprant after experiencing side effects from finasteride and disinterest in minoxidil. Some users express skepticism about setipiprant's effectiveness, while others encourage participation in the trial for potential benefits.

The conversation discusses a new model for understanding androgenetic alopecia (AGA), linking it to dietary and lifestyle factors similar to PCOS, and highlighting the role of DHT, vascular damage, and inflammation. Treatments mentioned include Minoxidil, finasteride, and RU58841.

The hair loss treatment Pyrilutamide and whether it has had any results for users. Martinsahara is planning to buy some soon.

Verteporfin and FAK inhibitors being looked at as potential treatments for hair regeneration, with updates on the unofficial off-label human trial being discussed.

Some users report minor hair regrowth using natural treatments like peppermint oil, dermarolling, and lifestyle changes, but results are limited. Others find more success with treatments like minoxidil, finasteride, and nizoral, while some remain skeptical of natural methods.

Eli Lilly's drug baricitinib showed effectiveness in treating alopecia areata, with higher doses resulting in significant hair regrowth compared to placebo. The treatment is not for male pattern baldness.

GT20029 is a new hair loss treatment in Phase 3 trials in China, using PROTAC technology to target androgen receptors, potentially with fewer side effects than finasteride and minoxidil. VDPHL01, a second-generation minoxidil, is also mentioned as potentially more effective.

A user is advocating for Phase 3 trials of the hair loss treatment PP405 to be conducted in Germany, citing benefits like a diverse patient base and faster access for European patients. Despite skepticism about the petition's influence, the user believes it can demonstrate significant interest and potentially influence strategic decisions.

User experienced hair regrowth using Min, Fin, RU, micro needling, and keto. Others encouraged consistency and shared excitement for future progress.

The conversation is about the anticipation of results for a hair loss treatment study, specifically for GT20029, with expectations for the results to be released in the first quarter of 2024. No specific treatments were discussed.

The user shared their nearly 3-year hair loss treatment journey, starting with minoxidil, then adding finasteride, nizoral shampoo, and microneedling, later incorporating oral minoxidil and RU58841, and recently switching to dutasteride. They are considering replacing RU58841 with pyrilutamide and are aware of the potential side effects of oral minoxidil on heart health.

The conversation is about whether a doctor is needed for injections of a product called SCUBE3 for hair loss. No specific treatments were discussed.

A 26-year-old male is still experiencing hair loss after a year of using Dutasteride and is considering using CB0301 (Breezula) to block all androgens on his follicles. He is looking for a reliable source to purchase CB0301 and inquires about the availability of a premade solution.

Corticosterone inhibits GAS6, affecting hair follicle stem-cell activity, with potential implications for stress-related hair loss. Ashwagandha and Vitamin K are suggested for reducing cortisol, but their effectiveness is debated.

The conversation discusses the high cost of CB-03-01, a topical antiandrogen for hair loss, which is considered safe and remains localized upon application. It questions whether the expense is justified compared to the lower risks it poses relative to finasteride.

PP405 shows promise in hair loss treatment, but stem cell therapy using adipose-derived stem cells and ATP also successfully reversed androgenetic alopecia in mice. Stem cell therapy is costly, and some doubt the effectiveness of PP405 based on press releases.

The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.

Actifolic RU-58841 powder and GhK-Cu peptide were tested and found to be accurate. The user is satisfied with the product's authenticity for hair loss treatment.

RU58841 not working for hair loss after 10 months. Concerns about purity of experimental drugs.

The user increased their steroid dosage and noticed hair shedding, so they adjusted their regimen by reducing steroid doses and adding oral dutasteride. They are also experimenting with combining RU-58841 and KX-826/pyrilutamide in minoxidil to address hair loss.

The conversation is about skepticism regarding new hair loss treatments until they are FDA approved. People have been joking about treatments being 5-7 years away for decades.

The "Big 3 Stack" for hair loss treatment, which includes Minoxidil for hair density improvement, Ketoconazole shampoo for enhancing hair volume and thickness, and Finasteride for blocking hair loss causing hormones. Microneedling can boost Minoxidil's effects.